ActiGraph, the global leader in wearable digital health technology for clinical research and development, has announced the acquisition of Biofourmis Connect, a division of Biofourmis that delivers an ...

This is the second volume of the Research Topic titled 'Novel Insights into CAR T-cell Associated Neurotoxicity'. You may ...

Cabaletta Bio’s financials and CAR T-cell therapy show potential but face risks. Discover why CABA stock is a risky yet ...

T-cell therapy yielded encouraging response rates and safety findings among patients with relapsed or refractory chronic ...

CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...

Itolizumab is under clinical development by Biocon and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with ...

At the recent American Society of Hematology annual meeting, early data from the Mithic-FL1 Trial demonstrated impressive ...

Treatment-related adverse events (TRAEs) were reported in all patients. The most common TRAE was cytokine release syndrome ...

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses ...